DAX19.146 +0,7%ESt504.756 +0,6%MSCIW3.755 +0,6%Dow43.944 +1,2%Nas18.991 +0,1%Bitcoin93.699 +4,9%Euro1,0486 -0,5%Öl73,82 +1,0%Gold2.672 +0,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 MicroStrategy 722713 Tesla A1CX3T Bayer BAY001 Rheinmetall 703000 Porsche PAG911 Volkswagen (VW) vz. 766403 Coinbase A2QP7J Amazon 906866 Mercedes-Benz Group (ex Daimler) 710000 Palantir A2QA4J Siemens Energy ENER6Y Deutsche Telekom 555750 NEL ASA A0B733 EVOTEC 566480
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel weit im Plus -- NVIDIA übertrifft Erwartungen -- Bitcoin: Neuer Rekord -- Mercedes: Sparkurs -- MicroStrategy, Medios, Rheinmetall im Fokus
Top News
Bitcoin nähert sich Marke von 100.000 Dollar - Neuer Rekord bei über 98.300 Dollar Bitcoin nähert sich Marke von 100.000 Dollar - Neuer Rekord bei über 98.300 Dollar
CTS Eventim-Aktie bricht ein: Ziele nach zweistelligem Umsatz- und EBITDA-Plus bestätigt CTS Eventim-Aktie bricht ein: Ziele nach zweistelligem Umsatz- und EBITDA-Plus bestätigt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Redhill Biopharma Aktie

NeuKaufenVerkaufen
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone

WKNA1KBQX

ISINUS7574681034

SymbolRDHL

Redhill Biopharma Aktien News

DatumMeistgelesen
PR NewswireRedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
PR NewswireRedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
PR NewswireRedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
PR NewswireRedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
PR NewswireRedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
PR NewswireRedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
PR NewswireRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR NewswireNew Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
PR NewswireRedHill Biopharma Announces First Half 2024 Business Highlights
PR NewswireTalicia® Launched in the United Arab Emirates
PR NewswireRedHill Announces Positive Obesity and Diabetes Results with Opaganib
PR NewswireRedHill Biopharma Announces Plan to Implement ADS Ratio Change
PR NewswireNewly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease
PR NewswireRedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
PR NewswireRedHill Biopharma Terminates License Agreement for Aemcolo®
PR NewswireRedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
PR NewswireRedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
PR NewswireRedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
PR NewswireRedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
PR NewswireRedHill Announces New USPTO Patent Covering Talicia® Through 2034
PR NewswireRedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
PR NewswireRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
PR NewswireRedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
PR NewswireRedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
PR NewswireRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR NewswireRedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
BenzingaWhat's Going On With Redhill Biopharma Stock?
BenzingaWhy Is Gastrointestinal Disease Focused-RedHill Biopharma Stock Higher Over 100% Today?
PR NewswireRedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
PR NewswireRedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
PR NewswireRedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
PR NewswireRedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
PR NewswireRedHill Announces FDA sNDA Approval for Talicia®
PR NewswireRedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
PR NewswireRedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
PR NewswireRedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
PR NewswireRedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
PR NewswireRedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
PR NewswireRedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
PR NewswireRedHill Provides R&D Update

Redhill Biopharma News

Redhill Biopharma News: auf dieser Seite finden Sie alle Redhill Biopharma News und Nachrichten zur Redhill Biopharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Redhill Biopharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Redhill Biopharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.